Lily has issued voluntary licenses for Barcitinib to six Indian drug makers besides Natco, these include- Sun Pharma, Cipla, Dr Reddy’s, Lupin, Torrent Pharma and MSN Labs. Barcitinib, in combination with Remdesivir, received emergency approval last year from the USFDA for treatment of hospitalized Covid19 patients who are not on ventilator.
